Did the atezolizumab trial show better progression-free survival for metastatic triple-negative breast cancer patients?

The question refers to the IMpassion130 trial, a phase III study that tested atezolizumab (an immunotherapy) combined with nab-paclitaxel chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC). The trial did show a significant improvement in progression-free survival (PFS) for patients whose tumors expressed PD-L1, leading to regulatory approval. However, results were not significant in the overall (unselected) population.

What the research says

The IMpassion130 trial, as described in a 2020 expert review, demonstrated a significant improvement in PFS when atezolizumab was added to nab-paclitaxel in patients with PD-L1-positive mTNBC ⁶. This benefit was the basis for FDA and EMA approval ⁶. A separate phase 2 trial (TBCRC 043) testing atezolizumab with carboplatin did not show a PFS benefit in the overall population, though biomarker analyses were ongoing ⁴. Network meta-analyses suggest that in PD-L1-positive mTNBC, pembrolizumab plus chemotherapy may be superior to atezolizumab plus nab-paclitaxel in terms of overall survival, but both are effective options ⁵. The ALICE trial also reported improved PFS with atezolizumab plus anthracycline-based chemotherapy, including in PD-L1-negative patients, and noted better quality of life ².

What to ask your doctor

• Is my tumor PD-L1 positive, and would I be a candidate for atezolizumab plus chemotherapy?
• What are the expected benefits in progression-free survival and overall survival with atezolizumab?
• How does atezolizumab compare to other immunotherapy options like pembrolizumab for my situation?
• What side effects should I expect from atezolizumab combined with chemotherapy?
• Are there ongoing clinical trials testing new combinations for metastatic triple-negative breast cancer?